Weight loss after treatment switch more likely for those with higher body mass
White blood cell changes on islatravir do not lead to a higher risk of infections
Switching to injectable cabotegravir and rilpivirine rarely affects body weight
Dolutegravir plus darunavir superior to three-drug darunavir combination in second-line treatment
Switching from TAF to older tenofovir may halt or reverse weight gain and lipid increases
Second-line HIV treatment durable for eight years in Uganda
‘Real world’ injectable treatment halves patient dissatisfaction, with only two viral failures in first six months
After viral rebound, dolutegravir-based treatment more likely to suppress HIV
Low-level HIV and viral load blips are important warning signals, European study finds
